Pfizer Inc. (NYSE:PFE) Stock Now Rated “Hold” by Sell-Side Brokerages

Pfizer Inc. (NYSE:PFE – Get Free Report) has earned a consensus recommendation of “Hold” from the twenty-two brokerages that are covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, fourteen have given a hold recommendation and six have issued a buy recommendation on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $30.32.

PFE has been the subject of several recent research reports. UBS Group lifted their target price on shares of Pfizer from $27.00 to $30.00 and gave the company a “neutral” rating in a report on Wednesday, November 4th. Argus set a $40.00 price target on Pfizer in a research note on Wednesday, November 4th. HSBC raised their price objective on Pfizer from $28.00 to $30.00 and gave the company a “hold” rating in a research report on Thursday, September 10th. Citigroup lifted their price objective on Pfizer from $27.00 to $30.00 and gave the company a “neutral” rating in a research note on Wednesday, November 4th. Finally, Wall Street Zen upgraded Pfizer from a “hold” rating to a “buy” rating in a research note on Saturday.

View Our Latest Stock Report on PFE

Latest Pfizer News

These are some of the PFE news items that stood out recently:

Hedge Funds Weigh In On Pfizer

Several large investors have recently modified their holdings of PFE. TOWER TRUST & INVESTMENT Co lifted its position in Pfizer by 1.9% in the third quarter. TOWER TRUST & INVESTMENT Co now owns 19,322 shares of the biopharmaceutical company’s stock valued at $551,000 after acquiring an additional 357 shares during the last quarter. Angeles Wealth Management LLC boosted its stake in Pfizer by 2.2% in the second quarter. Angeles Wealth Management LLC now owns 17,009 shares of the biopharmaceutical company’s stock valued at $410,000 after acquiring an additional 358 shares in the last quarter. Manchester Financial Inc. boosted its stake in Pfizer by 2.9% in the second quarter. Manchester Financial Inc. now owns 13,168 shares of the biopharmaceutical company’s stock valued at $317,000 after acquiring an additional 365 shares in the last quarter. Sumitomo Life Insurance Co. boosted its stake in Pfizer by 0.8% in the third quarter. Sumitomo Life Insurance Co. now owns 46,503 shares of the biopharmaceutical company’s stock valued at $1,326,000 after acquiring an additional 371 shares in the last quarter. Finally, Signature Equity Partners LLC grew its holdings in shares of Pfizer by 22.9% during the third quarter. Signature Equity Partners LLC now owns 2,067 shares of the biopharmaceutical company’s stock worth $59,000 after purchasing an additional 385 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Trading Down 0.0%

Shares of NYSE PFE opened at $28.89 on Monday. Pfizer has a 1 year low of $23.62 and a 1 year high of $31.44. The stock has a market cap of $164.65 billion, a P/E ratio of 41.27, a price-to-earnings-growth ratio of 1.90 and a beta of 0.31. The firm has a 50-day moving average of $28.80 and a 200 day moving average of $26.98. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.42 and a quick ratio of 1.10.

Pfizer (NYSE:PFE – Get Free Report) last announced its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.13. Pfizer had a net margin of 6.34% and a return on equity of 19.88%. The business had revenue of $16.58 billion for the quarter, compared to analysts’ expectations of $15.85 billion. During the same quarter in the prior year, the company earned $0.87 earnings per share. The business’s revenue was down .4% compared to the same quarter last year. As a group, sell-side analysts expect that Pfizer will post 3.04 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 7th. Stockholders of record on Friday, November 6th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, November 6th. This represents a $1.72 annualized dividend and a dividend yield of 6.0%. Pfizer’s dividend payout ratio (DPR) is presently 245.71%.

Pfizer Company Profile

(Get Free Report)

Pfizer Inc. is a global biopharmaceutical company that researches, develops, manufactures and commercializes prescription medicines and vaccines. Its work spans areas including oncology, vaccines, internal medicine, inflammation and immunology, rare diseases, and infectious diseases. The company’s products include the Prevnar family of vaccines and medicines such as Eliquis, which it commercializes with Bristol Myers Squibb, and Paxlovid. Pfizer also developed the Comirnaty COVID-19 vaccine with BioNTech.

Featured Stories

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.